Rachel Mata (Ram W Sabnis)

ORCID

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 244

Top Venues

ACS medicinal chemistry letters

Journal of natural products

This page only lists publications with an associated author ORCID identifier.

Publications

Rachel Mata
Novel ACC Inhibitors for Treating Acne. ACS medicinal chemistry letters 15 (4) (2024)
Rachel Mata
Pyrrolidinone Derivatives as NIK Inhibitors for Treating Inflammatory and Autoimmune Diseases. ACS medicinal chemistry letters 15 (3) (2024)
Rachel Mata
Combination of Allosteric and Orthosteric EGFR Inhibitors for Treating Non-Small-Cell Lung Cancer. ACS medicinal chemistry letters 15 (3) (2024)
Rachel Mata, Anika R Sabnis
3-Alkynyl Carboxamides as AEP Modulators for Treating Alzheimer's Disease. ACS medicinal chemistry letters 15 (2) (2024)
Rachel Mata
Novel CD73 Inhibitors for Treating Cancer. ACS medicinal chemistry letters 15 (5) (2024)
Rachel Mata
Novel KRAS Inhibitors for Treating Non-Small-Cell Lung Cancer. ACS medicinal chemistry letters 15 (6) (2024)
Rachel Mata
Novel AT2R Antagonists for Treating Chronic Pain. ACS medicinal chemistry letters 15 (3) (2024)
Rachel Mata
Novel Heterocyclic Compounds as Monoacylglycerol Lipase Inhibitors for Treating Multiple Diseases. ACS medicinal chemistry letters 15 (7) (2024)
Rachel Mata
Novel AHR Agonists for Treating Psoriasis and Atopic Dermatitis. ACS medicinal chemistry letters 15 (7) (2024)
Rachel Mata
Novel Imidazopyridine and Imidazopyridazine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases. ACS medicinal chemistry letters 15 (8) (2024)
Rachel Mata
Novel Cyanopyridine Compounds as KHK Inhibitors for Treating NAFLD, NASH, and Type II Diabetes. ACS medicinal chemistry letters 15 (8) (2024)
Rachel Mata
Novel Heterocyclic PAD4 Inhibitors for Treating Multiple Diseases. ACS medicinal chemistry letters 15 (2) (2024)
Rachel Mata
Novel CD73 Inhibitors for Treating Cancer. ACS medicinal chemistry letters 15 (5) (2024)
Rachel Mata
Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases. ACS medicinal chemistry letters 15 (2) (2024)
Rachel Mata
Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis. ACS medicinal chemistry letters 15 (2) (2024)
Rachel Mata
Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases. ACS medicinal chemistry letters 15 (2) (2024)
Rachel Mata
Novel Exatecan-Derived Topoisomerase-1 Inhibitors for Treating Cancer. ACS medicinal chemistry letters 15 (5) (2024)
Rachel Mata
Novel Compounds as NLRP3 Inhibitors for Treating Alzheimer's Disease and Parkinson's Disease. ACS medicinal chemistry letters 15 (8) (2024)
Rachel Mata
Novel PCSK9 Inhibitors for Treating Cardiovascular Diseases. ACS medicinal chemistry letters 15 (4) (2024)
Rachel Mata
Novel Compounds as NLRP3 Inhibitors for Treating Alzheimer's Disease and Parkinson's Disease. ACS medicinal chemistry letters 15 (8) (2024)
Rachel Mata
Novel Tyrosine Kinase 2 Inhibitors for Treating Autoimmune and Inflammatory Diseases. ACS medicinal chemistry letters 15 (6) (2024)
Rachel Mata
Pyrrolidinone Derivatives as NIK Inhibitors for Treating Autoimmune and Inflammatory Diseases. ACS medicinal chemistry letters 15 (5) (2024)
Rachel Mata
Novel Heterocyclic PAD4 Inhibitors for Treating Multiple Diseases. ACS medicinal chemistry letters 15 (2) (2024)
Rachel Mata
Novel Exatecan-Derived Topoisomerase-1 Inhibitors for Treating Cancer. ACS medicinal chemistry letters 15 (5) (2024)
Rachel Mata
TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases. ACS medicinal chemistry letters 15 (3) (2024)
Rachel Mata
Novel Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, Namely, Narcolepsy and Hypersomnia. ACS medicinal chemistry letters 15 (8) (2024)
Rachel Mata
Imidazopyridine Compounds as ERK5 Inhibitors for Treating Cancer. ACS medicinal chemistry letters 15 (6) (2024)
Rachel Mata
Novel Tetrahydropyrido[3,4- d ]pyrimidines as HPK1 Inhibitors for Treating Cancer, Inflammatory, and Autoimmune Diseases. ACS medicinal chemistry letters 15 (3) (2024)
Rachel Mata
Novel Heteroaryl Fluoroalkenes as DGK Inhibitors for Treating Cancer, Particularly Metastatic Melanoma. ACS medicinal chemistry letters 15 (9) (2024)
Rachel Mata
Novel Heteroaryl Compounds as CD73 Inhibitors for Treating Cancer. ACS medicinal chemistry letters 15 (6) (2024)
Rachel Mata
Novel Furopyridine and Furopyrimidine Compounds as PI4K Inhibitors for Treating Malaria and Viral Infection. ACS medicinal chemistry letters 15 (6) (2024)
Rachel Mata
Novel KRAS Inhibitors for Treating Non-Small-Cell Lung Cancer. ACS medicinal chemistry letters 15 (6) (2024)
Rachel Mata
Novel PARP1 Inhibitors for Treating Cancer. ACS medicinal chemistry letters 15 (2) (2024)
Rachel Mata
Novel Papain-Like Protease Inhibitors for Treating Viral Infections, in particular, Coronavirus Infections. ACS medicinal chemistry letters 15 (8) (2024)
Rachel Mata
Novel Heterocyclic PAD4 Inhibitors for Treating Diseases. ACS medicinal chemistry letters 15 (3) (2024)
Rachel Mata
Novel Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases. ACS medicinal chemistry letters 15 (9) (2024)
Rachel Mata
Novel Phosphorylpurinone Compounds for Treating Cancer. ACS medicinal chemistry letters 15 (4) (2024)
Rachel Mata
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases. ACS medicinal chemistry letters 15 (8) (2024)
Rachel Mata
Novel AHR Agonists for Treating Psoriasis and Atopic Dermatitis. ACS medicinal chemistry letters 15 (7) (2024)
Rachel Mata
Novel Cyanopyridine Compounds as KHK Inhibitors for Treating NAFLD, NASH, and Type II Diabetes. ACS medicinal chemistry letters 15 (8) (2024)
Rachel Mata
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases. ACS medicinal chemistry letters 15 (8) (2024)
Rachel Mata
Pyrrolidinone Derivatives as NIK Inhibitors for Treating Autoimmune and Inflammatory Diseases. ACS medicinal chemistry letters 15 (5) (2024)
Rachel Mata
MALT1 Inhibitors for Treating Cancer and Immunological Diseases. ACS medicinal chemistry letters 15 (9) (2024)
Rachel Mata
Novel AT2R Antagonists for Treating Chronic Pain. ACS medicinal chemistry letters 15 (3) (2024)
Rachel Mata
Combination of Allosteric and Orthosteric EGFR Inhibitors for Treating Non-Small-Cell Lung Cancer. ACS medicinal chemistry letters 15 (3) (2024)
Rachel Mata
Novel 2,7-Naphthyridine Compounds as MASTL Inhibitors for Treating Cancer. ACS medicinal chemistry letters 15 (6) (2024)
Rachel Mata
Novel Heterocyclic PAD4 Inhibitors for Treating Diseases. ACS medicinal chemistry letters 15 (3) (2024)
Rachel Mata
Novel Furopyridine and Furopyrimidine Compounds as PI4K Inhibitors for Treating Malaria and Viral Infection. ACS medicinal chemistry letters 15 (6) (2024)
Rachel Mata
Novel PCSK9 Inhibitors for Treating Cardiovascular Diseases. ACS medicinal chemistry letters 15 (4) (2024)
Rachel Mata
Novel Glucagon-like Peptide 1 Receptor Agonists for Treating Type II Diabetes. ACS medicinal chemistry letters 15 (8) (2024)
Rachel Mata
Novel HSD17B13 Inhibitors for Treating Liver Diseases. ACS medicinal chemistry letters 15 (6) (2024)
Rachel Mata
Novel PARP1 Inhibitors for Treating Cancer. ACS medicinal chemistry letters 15 (2) (2024)
Rachel Mata
Novel Phosphorylpurinone Compounds for Treating Cancer. ACS medicinal chemistry letters 15 (4) (2024)
Rachel Mata
Novel Myeloperoxidase Inhibitors for Treating Multiple Diseases. ACS medicinal chemistry letters 15 (5) (2024)
Rachel Mata
Novel HSD17B13 Inhibitors for Treating Liver Diseases. ACS medicinal chemistry letters 15 (6) (2024)
Rachel Mata
Novel Heterocyclic Compounds as Monoacylglycerol Lipase Inhibitors for Treating Multiple Diseases. ACS medicinal chemistry letters 15 (7) (2024)
Rachel Mata
Novel Tyrosine Kinase 2 Inhibitors for Treating Autoimmune and Inflammatory Diseases. ACS medicinal chemistry letters 15 (6) (2024)
Rachel Mata
Novel Tetrahydropyrido[3,4- d ]pyrimidines as HPK1 Inhibitors for Treating Cancer, Inflammatory, and Autoimmune Diseases. ACS medicinal chemistry letters 15 (3) (2024)
Rachel Mata
Novel KRAS Inhibitors for Treating Non-small Cell Lung Cancer. ACS medicinal chemistry letters 15 (8) (2024)
Rachel Mata
TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases. ACS medicinal chemistry letters 15 (3) (2024)
Rachel Mata, Anika R Sabnis
Novel Heterocyclic Compounds for Treating Huntington's Disease. ACS medicinal chemistry letters 15 (3) (2024)
Rachel Mata
Novel Myeloperoxidase Inhibitors for Treating Multiple Diseases. ACS medicinal chemistry letters 15 (5) (2024)
Rachel Mata
Novel Glucagon-like Peptide 1 Receptor Agonists for Treating Type II Diabetes. ACS medicinal chemistry letters 15 (8) (2024)
Rachel Mata
Pyrrolidinone Derivatives as NIK Inhibitors for Treating Inflammatory and Autoimmune Diseases. ACS medicinal chemistry letters 15 (3) (2024)
Rachel Mata
Novel Isoxazolidines as RIPK1 Inhibitors for Treating Alzheimer's Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis. ACS medicinal chemistry letters 15 (4) (2024)
Rachel Mata, Anika R Sabnis
3-Alkynyl Carboxamides as AEP Modulators for Treating Alzheimer's Disease. ACS medicinal chemistry letters 15 (2) (2024)
Rachel Mata
Novel Papain-Like Protease Inhibitors for Treating Viral Infections, in particular, Coronavirus Infections. ACS medicinal chemistry letters 15 (8) (2024)
Rachel Mata
Novel KRAS Inhibitors for Treating Non-small Cell Lung Cancer. ACS medicinal chemistry letters 15 (8) (2024)
Rachel Mata
Novel 2,7-Naphthyridine Compounds as MASTL Inhibitors for Treating Cancer. ACS medicinal chemistry letters 15 (6) (2024)
Rachel Mata
Novel Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, Namely, Narcolepsy and Hypersomnia. ACS medicinal chemistry letters 15 (8) (2024)
Rachel Mata
Imidazopyridine Compounds as ERK5 Inhibitors for Treating Cancer. ACS medicinal chemistry letters 15 (6) (2024)
Rachel Mata
Novel Azepino[4,5- b ]indolone as cGAS Inhibitors for Treating Immune-Mediated Diseases. ACS medicinal chemistry letters 15 (9) (2024)
Rachel Mata
Novel Imidazopyridine and Imidazopyridazine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases. ACS medicinal chemistry letters 15 (8) (2024)
Rachel Mata
Novel ACC Inhibitors for Treating Acne. ACS medicinal chemistry letters 15 (4) (2024)
Rachel Mata, Anika R Sabnis
Novel Heterocyclic Compounds for Treating Huntington's Disease. ACS medicinal chemistry letters 15 (3) (2024)
Rachel Mata
Novel Heteroaryl Compounds as CD73 Inhibitors for Treating Cancer. ACS medicinal chemistry letters 15 (6) (2024)
Rachel Mata
Novel Isoxazolidines as RIPK1 Inhibitors for Treating Alzheimer's Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis. ACS medicinal chemistry letters 15 (4) (2024)
Rachel Mata
Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis. ACS medicinal chemistry letters 15 (2) (2024)
Rachel Mata
Novel Compounds for Preventing SARS-CoV-2 Viral Replication and Treating COVID-19. ACS medicinal chemistry letters 14 (9) (2023)
Rachel Mata
Novel P2X3 Inhibitors for Treating Neurogenic Disorders. ACS medicinal chemistry letters 14 (9) (2023)
Rachel Mata
Novel PARP1 Inhibitors for Treating Cancer. ACS medicinal chemistry letters 14 (12) (2023)
Rachel Mata
Novel PARP7 Inhibitors for Treating Cancer. ACS medicinal chemistry letters 14 (12) (2023)
Rachel Mata
Novel 2,5-Diazabicyclo[4.2.0]octanes as GLP-1 Receptor Modulators for Treating Type 2 Diabetes. ACS medicinal chemistry letters 14 (6) (2023)
Rachel Mata
8-Aza Quinazolines as Brain Penetrant SOS1 Inhibitors for Treating Cancer. ACS medicinal chemistry letters 14 (11) (2023)
Rachel Mata
Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis. ACS medicinal chemistry letters 14 (10) (2023)
Rachel Mata
Novel Thienopyrrole Compounds for Treating Autoimmune Diseases and Inflammatory Conditions. ACS medicinal chemistry letters 14 (5) (2023)
Rachel Mata
1,2,4-Triazine Derivatives as NLRP3 Inhibitors for Treating Diseases. ACS medicinal chemistry letters 14 (5) (2023)
Rachel Mata, Anika R Sabnis
Novel Haloacethydrazides as AEP Inhibitors for Treating Alzheimer's Disease. ACS medicinal chemistry letters 14 (9) (2023)
Rachel Mata
Novel Pyrazolopyrazine Compounds as SHP2 Inhibitors for Treating Glioblastoma. ACS medicinal chemistry letters 14 (10) (2023)
Rachel Mata
Pyridazine Derivatives as NLRP3 Inhibitors for Treating Asthma, COPD, Parkinson's Disease, and Alzheimer's Disease. ACS medicinal chemistry letters 14 (8) (2023)
Rachel Mata
Novel Adenosine Receptor Antagonists for Treating Cancer and Immune-Related Disorders. ACS medicinal chemistry letters 14 (12) (2023)
Rachel Mata
Novel AHR Agonists for Treating Psoriasis. ACS medicinal chemistry letters 14 (5) (2023)
Rachel Mata
Novel PARP1 Inhibitors for Treating Cancer. ACS medicinal chemistry letters 14 (12) (2023)
Rachel Mata
Novel Aryl Hydrocarbon Receptor Agonists for Treating Psoriasis. ACS medicinal chemistry letters 14 (6) (2023)
Rachel Mata, Anika R Sabnis
Monoacylglycerol Lipase Modulators for Treating Autism Spectrum Disorders. ACS medicinal chemistry letters 14 (5) (2023)
Rachel Mata
Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia. ACS medicinal chemistry letters 14 (7) (2023)
Rachel Mata
Novel Lactams as CBL-B Inhibitors for Treating Cancer. ACS medicinal chemistry letters 14 (7) (2023)
Rachel Mata
Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis. ACS medicinal chemistry letters 14 (11) (2023)
Rachel Mata
Novel Compounds as TEAD Inhibitors for Treating Cancer. ACS medicinal chemistry letters 14 (9) (2023)
Rachel Mata
Novel Cyclopentathiophene Carboxamide Derivatives as PAFR Antagonists for Treating Ocular Diseases, Allergies, and Inflammation-Related Diseases. ACS medicinal chemistry letters 14 (9) (2023)

Rachel Mata.css-eqlu8i{font-size:small;padding-left:4px;} (Ram W Sabnis)

Publication Activity (10 Years)

Top Topics

Top Venues

Rachel Mata (Ram W Sabnis)